NovoCure Limited — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/95cbf965-5615-43a9-abc1-73512bef3eb9/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-136.0M | 2025-01-01 – 2025-12-31 | evidence 0001645113-26-000033 |
| FY 2024 | $-169.0M | 2024-01-01 – 2024-12-31 | evidence 0001645113-26-000033 |
| FY 2023 | $-207.0M | 2023-01-01 – 2023-12-31 | evidence 0001645113-26-000033 |
| FY 2022 | $-93.0M | 2022-01-01 – 2022-12-31 | evidence 0001645113-26-000033 |
| FY 2021 | $-58.0M | 2021-01-01 – 2021-12-31 | evidence 0001645113-26-000033 |
| FY 2020 | $19.8M | 2020-01-01 – 2020-12-31 | evidence 0001645113-21-000017 |
| FY 2019 | $-7.2M | 2019-01-01 – 2019-12-31 | evidence 0001645113-20-000025 |
| FY 2018 | $-63.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005146 |
| FY 2017 | $-61.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-002766 |
| FY 2016 | $-131.8M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-002097 |
| FY 2015 | $-111.6M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013777 |
| FY 2014 | $-80.7M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-008641 |
| FY 2013 | $-77.4M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-013777 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).